2022
Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clinical Cancer Research 2022, 29: 174-182. PMID: 36074155, PMCID: PMC9811155, DOI: 10.1158/1078-0432.ccr-22-1138.Peer-Reviewed Original ResearchConceptsBreast cancer brain metastasesActive brain metastasesObjective response rateCNS objective response rateCancer brain metastasesBrain metastasesT-DXdPatient-derived xenograftsPDX modelsCohort studyTrastuzumab deruxtecanClinical efficacyClinical trialsHER2-positive breast cancer brain metastasesMetastatic HER2-positive breast cancerResponse rateMulti-institutional cohort studyHER2-positive breast cancerRetrospective multi-institutional cohort studyOrthotopic patient-derived xenograftsRetrospective cohort studyProspective clinical trialsSubset of patientsCentral nervous system activityPivotal clinical trials
2021
How we treat HER2-positive brain metastases
Stavrou E, Winer EP, Lin NU. How we treat HER2-positive brain metastases. ESMO Open 2021, 6: 100256. PMID: 34482180, PMCID: PMC8424223, DOI: 10.1016/j.esmoop.2021.100256.Peer-Reviewed Original ResearchConceptsHER2-positive brain metastasesHuman epidermal growth factor 2Brain metastasesAdvanced diseaseBreast cancerCentral nervous system metastasesHER2-positive breast cancerEpidermal growth factor 2Nervous system metastasesExperienced multidisciplinary teamSurvival of patientsCentral nervous system activitySite of diseaseNervous system activityUnique clinical challengesAssociated morbiditySystemic therapyGrowth factor 2Clinical challengeReview of agentsClinical scenariosMultidisciplinary teamMetastasisSystem activityDisease